BioSpace News Archive

The U.S. Food and Drug Administration and the U.S. Drug Enforcement Administration recently issued joint warning letters to operators of two websites illegally selling Schedule II stimulants, including amphetamine drug products marketed as Adderall.

Increasing prevalence of chronic diseases, rising number of surgical procedures, and growing preference for minimally invasive surgeries are some key factors expected to drive global market growth.

Increasing prevalence of chronic diseases, growing demand for handheld scanners, and increasing awareness about early diagnosis and treatment are some key factors expected to drive global market growth.

Increasing research in biotechnology and pharmaceutical sector, rising global prevalence of infectious and chronic diseases, and rapid advancements in protein therapeutics are some key factors expected to drive market revenue growth.

Apotex Corp. announced today its release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States.

Lysogene (FR0013233475 – LYS) (Paris:LYS), announced today that it has exercised its option to enter into an exclusive worldwide license agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, for the development and commercialization of a gene therapy candidate for the treatment of neuronopathic Gaucher disease and Parkinson disease (PD) with GBA1 mutations.

Chimeron Bio, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, to advance the Company’s Oncology portfolio to the clinic.

Gain Therapeutics, Inc., a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, presented new pre-clinical data from its Parkinson’s Disease program.

LIXTE Biotechnology Holdings, Inc., a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced that it has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE’s common stock, at a purchase price of $2.00 per share, in a registered direct offering.

Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, announced that Dr. Peter Farrell and Michael E. Lehman have joined the Company’s Board of Directors.